GENELUX Corp — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Thomas John | — | Sale | 10,000 | $5.00 | $50,000 | 492,784 | Dec 1, 2025 |
| Zindrick Thomas | President and CEO | Sale | 12,673 | $3.33 | $42,201 | 542,940 | Nov 17, 2025 |
| Cappello Joseph | Chief Technical Officer | Sale | 1,463 | $3.36 | $4,916 | 157,033 | Nov 17, 2025 |
| Smalling Ralph | Head of Regulatory | Sale | 165 | $4.69 | $774 | 68,658 | Nov 17, 2025 |
| Smalling Ralph | Head of Regulatory | Award / Grant | 10,000 | — | — | 70,990 | Sep 1, 2025 |
| Zindrick Thomas | President and CEO | Award / Grant | 361,200 | — | — | 554,161 | Aug 27, 2025 |
| Thomas John | — | Award / Grant | 22,283 | — | — | 502,784 | Aug 27, 2025 |
| Mirabelli Mary | — | Award / Grant | 22,283 | — | — | 73,284 | Aug 27, 2025 |
| Yu Yong | SVP, Clinical Development | Award / Grant | 101,480 | — | — | 150,036 | Aug 27, 2025 |
| Smalling Ralph | Head of Regulatory | Award / Grant | 26,230 | — | — | 60,990 | Aug 27, 2025 |
| Cappello Joseph | Chief Technical Officer | Award / Grant | 107,500 | — | — | 159,766 | Aug 27, 2025 |
| Smither John W | — | Award / Grant | 22,283 | — | — | 74,994 | Aug 27, 2025 |
| Tyree James L | — | Award / Grant | 22,283 | — | — | 68,074 | Aug 27, 2025 |
| Yu Yong | SVP, Clinical Development | Sale | 973 | $5.37 | $5,225 | 145,844 | Aug 21, 2025 |
| Thomas John | — | Gift | 25,000 | — | — | 480,501 | Jun 6, 2025 |
| Ryder Sean | General Counsel | Sale | 4,475 | $2.92 | $13,067 | 47,621 | May 12, 2025 |
| Zindrick Thomas | President and CEO | Sale | 10,764 | $2.92 | $31,431 | 191,447 | May 12, 2025 |
| Yu Yong | VP, Clinical Trial Operations | Sale | 5,579 | $2.92 | $16,291 | 47,640 | May 12, 2025 |
| Cappello Joseph | VP, Pharmaceutical Development | Sale | 4,737 | $2.92 | $13,832 | 52,266 | May 12, 2025 |
| Smalling Ralph | Head of Regulatory | Sale | 1,259 | $2.92 | $3,676 | 34,760 | May 12, 2025 |
| Smalling Ralph | Head of Regulatory | Award / Grant | 4,172 | — | — | 36,019 | Mar 14, 2025 |
| Cappello Joseph | VP, Pharmaceutical Development | Award / Grant | 13,350 | — | — | 57,003 | Mar 14, 2025 |
| Yu Yong | VP, Clinical Trial Operations | Award / Grant | 13,350 | — | — | 53,219 | Mar 14, 2025 |
| Ryder Sean | General Counsel | Award / Grant | 10,708 | — | — | 52,096 | Mar 14, 2025 |
| Zindrick Thomas | President and CEO | Award / Grant | 30,339 | — | — | 202,211 | Mar 14, 2025 |
| Tyree James L | — | Sale | 3,460 | $2.46 | $8,512 | 45,791 | Dec 30, 2024 |
| Smalling Ralph | Head of Regulatory | Award / Grant | 15,525 | — | — | 31,847 | Dec 18, 2024 |
| Ryder Sean | General Counsel | Award / Grant | 22,000 | — | — | 41,388 | Dec 18, 2024 |
| Yu Yong | VP, Clinical Trial Operations | Award / Grant | 29,000 | — | — | 39,869 | Dec 18, 2024 |
| Cappello Joseph | VP, Pharmaceutical Development | Award / Grant | 29,000 | — | — | 43,653 | Dec 18, 2024 |
| Zak Lourie S. | Chief Financial Officer | Award / Grant | 41,650 | — | — | 82,452 | Dec 18, 2024 |
| Zindrick Thomas | President and CEO | Award / Grant | 134,500 | — | — | 171,872 | Dec 18, 2024 |
| Zindrick Thomas | President and CEO | Sale | 14,315 | $2.34 | $33,497 | 37,372 | Dec 16, 2024 |
| Zak Lourie S. | Chief Financial Officer | Sale | 2,103 | $2.34 | $4,921 | 40,802 | Dec 16, 2024 |
| Smalling Ralph | Head of Regulatory | Sale | 2,510 | $2.34 | $5,873 | 16,322 | Dec 16, 2024 |
| Cappello Joseph | VP, Pharmaceutical Development | Sale | 6,300 | $2.34 | $14,742 | 14,653 | Dec 16, 2024 |
| Szalay Aladar | — | Sale | 31,777 | $2.73 | $86,751 | 632,901 | Sep 13, 2024 |
| Tyree James L | — | Sale | 1,730 | $2.60 | $4,498 | 47,521 | Sep 11, 2024 |
| Szalay Aladar | — | Sale | 31,376 | $2.62 | $82,205 | 664,678 | Sep 9, 2024 |
| Szalay Aladar | — | Sale | 42,818 | $2.09 | $89,490 | 739,821 | Sep 3, 2024 |
| Szalay Aladar | — | Sale | 142,589 | $2.17 | $309,418 | 782,639 | Aug 28, 2024 |
| Szalay Aladar | — | Sale | 51,630 | $2.11 | $108,939 | 1,048,191 | Aug 23, 2024 |
| Tyree James L | — | Award / Grant | 39,541 | — | — | 49,251 | Aug 1, 2024 |
| Mirabelli Mary | — | Award / Grant | 39,541 | — | — | 52,001 | Aug 1, 2024 |
| Thomas John | — | Award / Grant | 39,541 | — | — | 505,501 | Aug 1, 2024 |
| Smither John W | — | Award / Grant | 39,541 | — | — | 52,711 | Aug 1, 2024 |
| Yu Yong | VP, Clinical Trial Operations | Award / Grant | 11,557 | — | — | 17,718 | Jun 24, 2024 |
| Tyree James L | — | Purchase | 6,250 | — | — | 9,710 | May 29, 2024 |
| Smither John W | — | Purchase | 6,250 | — | — | 13,170 | May 29, 2024 |
| Thomas John | — | Purchase | 2,500 | — | — | 465,960 | May 29, 2024 |